Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Ondine Biomedical’s Steriwave technology to be piloted by The Ottowa Hospital

Product will be evaluated over a three-month period to prevent surgical site infections

Ondine Biomedical’s nasal photodisinfection technology is set to be piloted by The Ottowa Hospital (TOH) to reduce infections in spine surgery patients.

The Canada-based life sciences company’s universal, non-antibiotic protocol will be evaluated over a three-month period.

AIM-quoted Ondine's Steriwave™ technology has already been deployed in a number of Canadian hospitals, including Vancouver General and UBC Hospitals, where it has reduced post-operative infection rates for spine surgeries by 78%.

Steriwave fights infections through a process called 'nasal decolonisation' which acts as an effective and low-cost therapy to improves patient outcomes by reducing readmission rates and costs by rapidly eliminating the pathogens they are carrying.

Ondine’s chief executive officer Carolyn Cross commented: "We are very pleased to be working with the spine group at TOH to make our technology available to their patients.

"Following COVID-19, it is more important than ever to reduce patient readmission rates given the large surgery backlogs at all Canadian hospitals.”

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK